Latest Medicine stories from Life.
Johnson & Johnson is proceeding with its inflammatory bowel disease therapy, even though recent trials did not demonstrate a statistically significant benefit for patients.
This editorial examines the collaboration between the U.S. government and Gavi, the Vaccine Alliance, focusing on their efforts to enhance immunization access in lower-income countries.
A recent discussion highlights medical students' views on the integration of preventive care education in their curriculum, revealing concerns about coherence in their training.
Julia Vintarello is embarking on a new biotech venture aimed at addressing the commercial and regulatory hurdles in the production of customized medicines.
Recent research suggests that compounds found in ginger and turmeric may help combat antibiotic-resistant infections, particularly affecting vulnerable groups.
Recent advancements in copper-based single-atom nanozymes may enhance precision in malignant tumor therapies while minimizing side effects.
The U.S. Department of Health and Human Services (HHS) is appealing a ruling that impacts vaccine policy, following a lawsuit by the American Association of Pediatrics.
A new method for synthesizing polyfunctionalized biaryls without the use of transition-metal catalysts has been introduced by researchers at the Institute of Science Tokyo.
A group of medical students emphasizes the importance of integrating nutrition into medical training, advocating for a shift toward preventive health education.
While modern medicine aims to improve health, it often overlooks the importance of patient comfort and emotional well-being, leading many to seek alternative options.
The FDA commissioner highlights how real-time clinical trials could change the landscape of drug development by providing regulators with immediate data insights.
Industry leaders express significant worries regarding the implications of Trump's drug pricing plan, while Purdue Pharma's sentencing underscores persistent challenges in the pharmaceutical sector.
A recent recommendation to limit hepatitis B vaccinations at birth to only those infants deemed at risk raises alarms about potential increases in infections among newborns.
Erasca has reported that its experimental treatment for pancreatic and lung cancers has delivered results that exceed initial expectations in early trials.
The Trump administration has expressed concerns regarding the use of federal funds for fentanyl test strips, indicating a shift away from harm reduction strategies.
Astellas is moving forward with its XLMTM gene therapy trials despite earlier reports of deaths. Meanwhile, Veradermics celebrates success in its hair loss pill trial, and the FDA accelerates reviews for psychedelics.
In the podcast "Drug Story," host Thomas Goetz discusses how society often misuses medications like Ambien and Ozempic, highlighting a disconnect between drug use and bodily needs.
A recent U.S. military strike on a suspected drug boat in the Eastern Pacific resulted in six fatalities, contributing to a rising death toll linked to anti-drug operations.
Today's health news highlights the growth of an international childhood vaccine campaign alongside a shift in GOP drug policy, signaling significant changes in public health efforts.
President Trump has finalized a series of drug pricing agreements, with the last deal involving Regeneron, marking the conclusion of 17 agreements pursued by the White House.